Quick Answer
enGene Therapeutics Inc. reported Diluted EPS of $2.29 per share for fiscal year 2025.
enGene Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.29 | +56.8% |
| 2024 | $1.46 | -99.0% |
| 2023 | $151.22 | +241.4% |
| 2022 | $44.30 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $0.44 | -8.3% | -22.8% |
| July 31, 2025 | $0.57 | +78.1% | +11.8% |
| April 30, 2025 | $0.51 | +34.2% | +6.3% |
| January 31, 2025 | $0.48 | +4.3% | +50.0% |
| July 31, 2024 | $0.32 | -96.3% | -15.8% |
| April 30, 2024 | $0.38 | -95.9% | -17.4% |
| January 31, 2024 | $0.46 | -96.5% | -94.6% |
| July 31, 2023 | $8.55 | — | -8.1% |
- enGene Therapeutics Inc. showed an increase of +56.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, enGene Therapeutics Inc.’s diluted eps has declined by 94.8% (from $44.30 per share to $2.29 per share).
- The most recent figure is from enGene Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: